Every 8-K that LB Pharmaceuticals Inc (LBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc (LBRX) reported the appointment of Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, under an at-will employment agreement. He brings more than two decades of finance leadership experience at public biotech and pharmaceutical companies, including roles at Aurinia Pharmaceuticals and Avalo Therapeutics.
Mr. Miller will receive an initial annual base salary of $530,000, with a target bonus equal to 40% of base salary, and an option to purchase 200,000 shares of common stock granted as an inducement award subject to four-year vesting. The agreement provides enhanced severance and benefit continuation if he is terminated without cause or resigns for good reason, with additional cash and full equity acceleration in connection with a change of control. A concurrent press release highlights his experience guiding companies from pivotal data through commercialization as LB Pharmaceuticals approaches pivotal NOVA-2 Phase 3 trial results and potential commercialization of LB-102 for schizophrenia.
LB Pharmaceuticals reported second quarter 2026 results and a corporate update centered on its lead neuropsychiatric candidate LB-102. The pivotal Phase 3 NOVA-2 trial in schizophrenia is enrolling faster than expected, with topline data now projected in the first half of 2027, followed by a planned pre-NDA FDA meeting in the second half of 2027. Additional Phase 2 trials in bipolar depression and adjunctive major depressive disorder are ongoing or planned, with key readouts expected from 2028–2029.
Liquidity is a major focus: cash, cash equivalents and marketable securities totaled $327.8 million as of June 30, 2026, and together with proceeds from a recent $150.0 million private placement are expected to fund operations beyond the second quarter of 2029 through multiple clinical milestones. The company is using this capital to expand LB-102 into new neuropsychiatric indications.
The investment phase is driving significantly higher spending. Research and development expense rose to $44.1 million in the quarter from $2.4 million a year earlier, contributing to a quarterly net loss of $51.6 million versus $4.9 million in the prior-year period. For the first six months of 2026, net loss was $70.7 million. The balance sheet shows total assets of $361.7 million and stockholders’ equity of $332.3 million as of June 30, 2026, reflecting a well-capitalized but loss-making development-stage profile.
On July 28, 2026, LB Pharmaceuticals Inc agreed to a private placement with institutional investors involving 3,577,560 shares of common stock and pre-funded warrants exercisable for up to 715,513 additional shares. Each share is priced at $34.94 and each pre-funded warrant at $34.9399, with a warrant exercise price of $0.0001 per share. The transaction is expected to close on or about July 30, 2026 and is anticipated to generate approximately $150 million in gross proceeds before expenses.
The company plans to use net proceeds, together with existing cash, to expand development of its lead candidate LB-102 into additional indications such as negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and for working capital and general corporate purposes. The pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership limits generally set at 4.99% or 9.99%, adjustable up to 19.99% with notice. LB Pharmaceuticals granted investors registration rights requiring an S-3 resale registration filing within 90 days of closing and efforts to keep it effective until the securities can be sold or resold under Rule 144 without restriction.
LB Pharmaceuticals Inc. announced that, based on enrollment projections, it now expects topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027, earlier than prior guidance of the second half of 2027, and plans a pre-NDA meeting with the FDA in the second half of 2027.
NOVA-2 is designed to enroll approximately 460 patients across 25 sites in the United States. The company states it remains well capitalized, with a cash runway expected to fund operations into the second quarter of 2029, including planned topline readouts from the Phase 2 ILLUMINATE-1 trial in bipolar depression in the first quarter of 2028 and from a Phase 2 trial in adjunctive major depressive disorder in the first half of 2029.
LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D. resigned her officer role effective June 15, 2026, for personal reasons and will transition to an advisor role. She will continue providing full-time consulting services through September 15, 2026 while the company searches for a replacement.
The company states that her departure is not related to its clinical program operations or practices and does not expect a material impact on clinical development activities or previously disclosed milestones. Existing clinical development and operations teams will keep overseeing ongoing trials.
Under a Separation and Consulting Agreement dated June 8, 2026, if Dr. Eramo serves through the consulting period and complies with her obligations, she will receive her current base salary paid monthly until June 15, 2027, a prorated 2026 target bonus, and accelerated vesting of 66,143 unvested option shares on September 15, 2026. Her other options continue vesting under existing equity plans, and the company will reimburse COBRA healthcare premiums for up to 12 months, subject to earlier termination conditions.
LB Pharmaceuticals Inc. reported the results of its 2026 Annual Meeting of Stockholders. Three Class I directors — Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum — were elected to three-year terms ending at the 2029 annual meeting.
Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with a strong majority of votes cast in favor and minimal opposition or abstentions.
LB Pharmaceuticals reported first quarter 2026 results and highlighted progress on its lead drug LB-102 across multiple neuropsychiatric indications. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $365.6 million, which it expects will fund operations into the second quarter of 2029.
Research and development expenses rose to $14,645 thousand from $3,421 thousand a year earlier, and general and administrative expenses increased to $7,459 thousand from $3,008 thousand, leading to a net loss of $19,054 thousand versus $5,306 thousand. The pivotal Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression have been initiated, with additional Phase 2 work in adjunctive major depressive disorder planned following a $100 million private placement.
LB Pharmaceuticals reported another net loss for 2025 but with a much stronger balance sheet and advancing clinical pipeline. Net loss for 2025 was about $25.2 million, a sharp improvement from $63.1 million in 2024, as operating loss narrowed and non-operating income increased.
Cash, cash equivalents and investments were $295.2 million as of December 31, 2025, compared with $28.0 million a year earlier, supported by an IPO and a recent $100 million private placement. The company expects this to fund operations into the second quarter of 2029.
Operationally, LB reported positive Phase 2 results for LB-102 in acute schizophrenia and has started the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression, with a Phase 2 adjunctive MDD study planned for early 2027.
LB Pharmaceuticals Inc reported that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His current term will end at the conclusion of that meeting, and he will continue serving on the Board and the Nominating and Corporate Governance Committee until then.
The company stated that Mr. Prensky’s decision was not due to any disagreement regarding operations, policies, or practices. After his Board service ends, he is expected to provide consulting services under an amended Transition, Separation, and Consulting Agreement, which allows his unvested stock options to continue vesting during the agreement term.
LB Pharmaceuticals Inc appointed Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director, with a term running through the 2026 annual stockholder meeting, and named him to the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Dr. Lenz will receive a $40,000 annual board retainer, a $5,000 annual committee retainer, an initial option to purchase 20,000 shares vesting over three years, and annual options for 10,000 shares vesting by the next annual meeting.
The Board also promoted Gad Soffer to Chief Operating and Business Officer, with at-will employment, an annual base salary of $505,000, and eligibility for an annual bonus targeted at 40% of base salary. The company describes itself as a late-stage biopharmaceutical firm advancing lead candidate LB-102 for multiple neuropsychiatric indications.
LB Pharmaceuticals Inc entered into a private placement financing, agreeing to sell 3,306,571 common shares and pre-funded warrants for up to 1,417,107 additional shares at prices around $21.17 per share, for estimated gross proceeds of about $100 million.
The company plans to use the net proceeds mainly to fund a Phase 2 trial of LB-102 as an adjunctive treatment for major depressive disorder, as well as for working capital and general corporate purposes. The multi-center, six-week trial is expected to enroll about 380 patients across roughly 50 sites in the U.S. and Europe.
LB Pharmaceuticals (LBRX) amended its headquarters lease to add 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The underlying lease term remains scheduled to expire on March 31, 2032.
The landlord shall endeavor to deliver the Expansion Premises on or prior to July 1, 2026. From the Expansion Premises Commencement Date, fixed rent for the added space will be $430,962 per year for the first three years, increasing to $477,302 per year on the third anniversary. The parties agreed to a fixed rent abatement for the first 150 days after commencement, as set forth in the amendment.
LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release. The company also plans to grant her an equity award as an inducement to join, made outside of—but subject to—the 2025 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is filed as Exhibit 99.1.
LB Pharmaceuticals (LBRX) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 via an 8-K.
The disclosure under Item 2.02 is expressly stated as “furnished,” not “filed,” which limits its application under Section 18 of the Exchange Act. The filing lists the company’s common stock on The Nasdaq Stock Market under the symbol LBRX, and is signed by Chief Executive Officer Heather Turner.